Form 4: Verastem CFO Daniel Calkins Exchanges Stock Options in Company Program
SEC Form 4
Verastem's Chief Financial Officer, Daniel Calkins, participated in an option exchange program, canceling existing options and receiving new grants with adjusted vesting schedules.
Summary
- Daniel Calkins, the CFO of Verastem, Inc., participated in the company's option exchange program on March 11, 2024.
- As part of the program, Calkins canceled certain unexercised stock options with an exercise price greater than $15.
- In exchange, Calkins received new stock options.
- For fully vested canceled options, Calkins received 5,413 stock options that will vest in two equal installments over two years from March 11, 2024.
- For unvested canceled options, Calkins received 1,175 stock options that will vest as to 25% on the first anniversary of the grant date and an additional 6.25% at the end of each successive three-month period until the fourth anniversary.
- The new options are subject to Calkins' continued service to Verastem.
Sentiment
Score: 6
Explanation: The document describes a routine executive compensation adjustment. It's neither particularly positive nor negative, but reflects ongoing management of employee incentives.
Positives
- The option exchange program may incentivize continued service from the CFO.
- The exchange simplifies Calkins' option holdings.
Industry Context
Option exchange programs are a fairly common practice in the biotech industry to refresh employee incentives and align them with the company's current stock price and strategic goals.
Comparison to Industry Standards
- Many biotech companies use stock options as a key component of their compensation packages, similar to Verastem.
- Vesting schedules are also standard, often ranging from two to four years, aligning with typical industry practices.
- Companies like Amgen, Gilead, and Biogen also utilize stock options extensively, with similar vesting periods and performance-based criteria.
Stakeholder Impact
- Shareholders may see this as a way to retain and incentivize key executives.
- Employees may view the option exchange program as a positive adjustment to their compensation packages.
Key Dates
| Date | Description |
|---|---|
| 01/02/2019 | Date of canceled option grant with vesting terms. |
| 06/21/2019 | Date of canceled option grant with vesting terms. |
| 12/20/2019 | Date of canceled option grant with vesting terms. |
| 04/01/2020 | Date of canceled option grant with vesting terms. |
| 01/04/2021 | Date of canceled option grant with vesting terms. |
| 12/23/2021 | Date of canceled option grant with vesting terms. |
| 03/08/2024 | Date used to determine if options were fully vested for the exchange program. |
| 03/11/2024 | Date of the option exchange program and grant of new options. |
| 03/13/2024 | Date of the Form 4 filing. |
| 03/11/2034 | Expiration date of the newly granted stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.